
TVG’s CEO discusses the impact of a new £500,000 IUK/Defra grant
TVG’s CEO Jeremy Salt was interviewed by Stephen Gunnion of Proactive this week for the online news service Reach. In the interview Jeremy discusses the importance
Designed for a lifetime of active immunity – even in the presence of maternal antibodies

Providing expertise in veterinary medicine and market impact analysis

Microbiology and bioinformatics expertise with a focus on genomic characterisation

CRO with expertise in animal studies and challenge model development

Council of UK research and innovation supporting the most promising UK deep tech businesses.






Designed to overcome maternal-antibody interference enabling vaccination during the critical early-life window
Rapid, modular ‘plug and play’ Bacterial Artificial Chromosome (BAC)-based synthetic biology
Robust vector designed for sustained immune responses and long lasting protection
Ability to differentiate infected from vaccinated animals (DIVA), supporting surveillance programmes and regulatory acceptance
Targeting high-impact viral and bacterial diseases in livestock, with expansion into selected companion animal diseases.
Early-life respiratory protection in calves, including in the presence of maternally-derived antibodies (MDA).
Indicative at risk calf populations:
Market Opportunity:
BRSV sits within a significant cattle-health opportunity shaped by two major windows of vulnerability: early life, when maternally-derived antibodies can limit vaccine effectiveness, and post-weaning, when stress and commingling increase disease risk.
TVG’s lead programme is designed to address the early-life protection gap, with clear relevance in major cattle markets such as the UK and USA and broader significance across global livestock systems.
Stage:
Key Differentiators:

To find out more about our candidate vaccine pipeline, click below:
Cross-serotype bacterial protection in piglets, advancing vaccine solutions to antimicrobial resistance (AMR) and herd health.

Lumpy Skin Disease (LSD)
Bovine tuberculosis (bTB)
Bovine mastitis
African swine fever (ASF)
Porcine reproductive and respiratory syndrome (PRRS)
Porcine circovirus-2 (PCV2)
Porcine cysticercosis
Canine leishmaniasis
Feline immunodeficiency virus (FIV)
Equine influenza virus (EIV)
Canine oncology
Canine leishmaniasis
Feline immunodeficiency virus (FIV)
Equine influenza virus (EIV)
Canine oncology
Latest News

TVG’s CEO Jeremy Salt was interviewed by Stephen Gunnion of Proactive this week for the online news service Reach. In the interview Jeremy discusses the importance

The Vaccine Group (TVG) and the Animal and Plant Health Agency (APHA) have been awarded £500,000 through Defra’s Farming Innovation Programme, delivered in partnership with

The Vaccine Group (TVG) is pleased to announce that the full study underpinning its BRSV vaccine results is now available as a preprint on bioRxiv.

The Vaccine Group (TVG) is pleased to announce the appointment of Neil Crabb and Professor Laura Bowater, MBE, to its Board of Directors. Neil Crabb

The Vaccine Group was pleased to see TVG CEO Dr Jeremy Salt contribute expertise to the recent STAR IDAZ International Research Consortium meetings in Ottawa,

The Vaccine Group’s bovine respiratory syncytial virus (BRSV) vaccine programme has been recognised in the 2025 Animal Research Breakthroughs Review published by Understanding Animal Research, highlighting the
We use cookies to improve your experience on our site. By using our site, you consent to the use of cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
These cookies are needed for adding comments on this website.
Google reCAPTCHA helps protect websites from spam and abuse by verifying user interactions through challenges.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com (opens in a new window)
Marketing cookies are used to follow visitors to websites. The intention is to show ads that are relevant and engaging to the individual user.
LinkedIn Insight is a web analytics service that tracks and reports website traffic.
Service URL: www.linkedin.com (opens in a new window)
You can find more information in our Cookie Policy and Privacy Policy.